Compare the Immunogenicity, Reactogenicity and Safety of 2 Different Formulations of GSK Biologicals' Live Attenuated Human Rotavirus (HRV) Vaccine Given as a Two-Dose Primary Vaccination in Healthy Infants Previously Uninfected With HRV.

Trial Profile

Compare the Immunogenicity, Reactogenicity and Safety of 2 Different Formulations of GSK Biologicals' Live Attenuated Human Rotavirus (HRV) Vaccine Given as a Two-Dose Primary Vaccination in Healthy Infants Previously Uninfected With HRV.

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Sep 2016

At a glance

  • Drugs RIX 4414 (Primary)
  • Indications Rotavirus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 13 Jan 2011 Results published in Vaccine.
    • 09 Oct 2008 Checked against ClinicalTrials.gov record - last updated 9 Oct 2008.
    • 13 Apr 2007 Results have been reported.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top